Vicore Pharma Holding AB (publ) (FRA:6Y4)

Germany flag Germany · Delayed Price · Currency is EUR
1.134
-0.002 (-0.18%)
Last updated: Jan 28, 2026, 8:23 AM CET
66.52%
Market Cap298.23M +57.5%
Revenue (ttm)768.92K -91.8%
Net Income-38.39M
EPS-0.17
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open1.134
Previous Close1.136
Day's Range1.134 - 1.134
52-Week Range0.521 - 1.182
Betan/a
RSI49.75
Earnings DateFeb 27, 2026

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 36
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6Y4
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements